Conexeu Sciences Launches Preclinical Program for 3D-Printed Breast Matrix with Wake Forest Institute
Event summary
- Conexeu Sciences has initiated a preclinical development program for its B.R.E.A.S.T.™ bioregenerative matrix platform at the Wake Forest Institute for Regenerative Medicine.
- The program will evaluate the durability, host tissue integration, and resorbability of the CXU™ 3D-printed B.R.E.A.S.T.™ matrix.
- B.R.E.A.S.T.™ is designed as a resorbable and bioregenerative alternative to traditional breast implants.
- The company is leveraging support from the RegenMed Development Organization (ReMDO) ecosystem for advanced bioprinting infrastructure.
The big picture
Conexeu Sciences' collaboration with the Wake Forest Institute for Regenerative Medicine underscores the growing trend of biotechnology companies leveraging advanced bioprinting infrastructure to develop next-generation regenerative therapies. The shift from traditional implant technologies to bioregenerative approaches represents a significant evolution in the medical device industry, with potential implications for soft tissue restoration and reconstruction markets.
What we're watching
- Clinical Translation
- The pace at which preclinical findings will guide future studies and progression toward clinical development.
- Regulatory Strategy
- Whether Conexeu can sustain its predicate-based U.S. regulatory strategy with an anticipated 510(k) submission in early 2027.
- Market Expansion
- How the success of B.R.E.A.S.T.™ will affect Conexeu's expansion into other large, multi-billion-dollar end markets.
Related topics